Enterprise Value

5.359B

Cash

1.267B

Avg Qtr Burn

N/A

Short % of Float

2.98%

Insider Ownership

1.97%

Institutional Own.

89.03%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

CABOMETYX (cabozantinib) Details
Solid tumor/s, Renal cell carcinoma, Cancer

Approved

Quarterly sales

COMETRIQ (cabozantinib) Details
Metastatic MTC (Medullary Thyroid Cancer)

Approved

Quarterly sales

Zanzalintinib Details
Solid tumor/s, Cancer, Kidney cancer

Phase 3

Data readout

Phase 3

Data readout

CABOMETYX (cabozantinib) Details
Cancer, Pancreatic cancer

Phase 3

Update

CABOMETYX (cabozantinib) + atezolizumab Details
Solid tumor/s, Cancer, Castration-resistant prostate cancer

Phase 3

Update

Zanzalintinib + Pembrolizumab Details
Cancer, Head and neck squamous cell carcinoma

Phase 2/3

Data readout

Zanzalintinib + AB521 Details
Cancer, Kidney cancer

Phase 1/2

Initiation

Zanzalintinib Details
Solid tumor/s, Cancer

Phase 1b

Data readout

Zanzalintinib +/- atezolizumab Details
Solid tumor/s, Cancer, Carcinoma

Phase 1b

Update

Phase 1

Update